EDIT240830P10000
- 4.49
- 0.000.00%
Editas Medicine Newsroom
Editas Medicine Hold Rating With Revised Price Target Amidst Mixed Financial Signals
Buy Rating for Editas Medicine Backed by Strong Q2 Performance and Promising CRISPR Pipeline
Barclays Remains a Hold on Editas Medicine (EDIT)
Buy Rating on Editas Medicine as R&D Progress Signals Market Potential for Sickle Cell and Thalassemia Treatments
Editas Medicine Price Target Raised to $15.00/Share From $13.00 by B of A Securities
Editas Medicine Analyst Ratings
Truist Securities Adjusts Price Target on Editas Medicine to $12 From $20, Maintains Buy Rating
TD Cowen Sticks to Their Buy Rating for Editas Medicine (EDIT)
Editas Medicine Analyst Ratings
Editas Medicine Analyst Ratings
Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
Editas Medicine Analyst Ratings
Editas Medicine Upgraded at J.P. Morgan on Recent Weakness
Editas Medicine's Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy Rating
Maintaining a Hold: Editas Medicine Awaits Key Clinical Trial Results and Market Positioning
Buy Rating for Editas Medicine: Promising Trials and Solid Financial Footing Propel Growth Outlook
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Arcus Biosciences (RCUS) and Maravai Lifesciences Holdings (MRVI)
Strong Buy Rating for Editas Medicine: Promising Pipeline and Strategic IP Position Drive Optimism
Editas Medicine: Balanced Prospects and a Hold Rating With Modest Price Target Increase
The Latest Analyst Ratings For Editas Medicine